Enoticumab
Product Specifications
UNSPSC Description
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively[1].
Target Antigen
Notch
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling;Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/enoticumab.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
[Enoticumab]
References & Citations
[1]Kuhnert F, Chen G, Thurston G. Potent anti-tumor activity of blocking stromal Dll4 in ovarian xenograft models[J]. Cancer Research, 2013, 73(8_Supplement): 5091-5091.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99925/Enoticumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99925/Enoticumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
1192578-27-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
